Korean J Psychopharmacol.  2004 Jun;15(2):135-143.

Efficacy, Safety, and Tolerability of Quetiapine in Patients with Schizophrenia

  • 1Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
  • 2Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.


Atypical antipsychotics have an improved tolerability profile, and are less likely to cause debilitating extrapyramidal symptoms (EPS) than are the conventional antipsychotics. Quetiapine, the fourth atypical antipsychotic, was marketed in Korea as well as in the United States and is also available in over 70 countries worldwide. Quetiapine has been shown to be effective and well tolerated in patients particularly vulnerable to EPS related to conventional antipsychotics. In this article, we review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in treating patients with schizophrenia.


Atypical antipsychotics; Quetiapine; Schizophrenia
Full Text Links
  • KJP
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr